Is interleukin-1β a culprit in macrophage-adipocyte crosstalk in obesity?

Adipocyte

Volumn 4, Issue 2, 2015, Pages 149-152

  Bing, Chen ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Adi pose tissue; Adipocyte; Chemokine; Cytokine; Inflammation; Insulin resistance; Interleukin 1b; Macrophage; Obesity

Indexed keywords

CRYOPYRIN; GLUCOSE TRANSPORTER 4; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN RECEPTOR SUBSTRATE 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RANTES; TUMOR NECROSIS FACTOR ALPHA;

ADIPOCYTE; ADIPOGENESIS; ARTICLE; CELL INFILTRATION; CELL MIGRATION; GENE EXPRESSION; GLUCOSE TRANSPORT; HUMAN; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPOLYSIS; MACROPHAGE; MONOCYTE; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 84973928572     PISSN: 21623945     EISSN: 2162397X     Source Type: Journal    
DOI: 10.4161/21623945.2014.979661     Document Type: Article

References (49)

1. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Clee- man JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120:1640-5.
2. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003; 112:1821-30.
3. Odegaard JI, Chawla A. Pleiotropic actions of insulin resistance and inflammation in metabolic homeostasis. Science 2013; 339:172-7.
4. Lumeng CN, Saltiel AR. Inflammatory links between obesity and metabolic disease. J Clin Invest 2011; 121:2111-7.
5. Gesta S, Tseng YH, Kahn CR. Developmental origin of fat: tracking obesity to its source. Cell 2007; 131:242-56.
6. Bertola A, Ciucci T, Rousseau D, Bourlier V, Duffaut C, Bonnafous S, et al. Identification of adipose tissue dendritic cells correlated with obesity-associated insu- lin-resistance and inducing Th17 responses in mice and patients. Diabetes 2012; 61:2238-47.
7. Chawla A, Nguyen KD, Goh YP. Macrophage-mediated inflammation in metabolic disease. Nat Rev Immunol 2011; 11:738-49.
8. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW, Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112:1796-808.
9. McNelis JC, Olefsky JM. Macrophages, immunity, and metabolic disease. Immunity 2014; 41:36-48.
10. Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polari-zation. J Clin Invest 2007; 117:175-84. iol Endocrinol Metab 2007; 292:E166-74.
11. Fujisaka S, Usui I, Bukhari A, Ikutani M, Oya T, Kanatani Y, et al. Regulatory mechanisms for adipose tissue M1 and M2 macrophages in diet-induced obese mice. Diabetes 2009; 58:2574-82.
12. Wentworth JM, Naselli G, Brown WA, Doyle L, Phipson B, Smyth GK, et al. Pro-inflammatory CD11cCCD206C adipose tissue macrophages are associated with insulin resistance in human obesity. Diabetes 2010; 59:1648-56.
13. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011; 11:98-107.
14. Constant VA, Gagnon A, Landry A, Sorisky A. Macrophage conditioned medium inhibits the differentiation of 3T3-L1 and human abdominal preadipocytes. Diabetologia 2006; 49:1402-11.
15. Gao D, Trayhurn P, Bing C. Macrophage-secreted factors inhibit ZAG expression and secretion by human adipocytes. Mol Cell Endocrinol 2010; 325:135-42.
16. Lacasa D, Taleb S, Keophiphath M, Miranville A, Clement K. Macrophage-secreted factors impair human adipogenesis: involvement of proinflammatory state in preadipocytes. Endocrinology 2007; 148:868-77.
17. Gagnon A, Foster C, Landry A, Sorisky A. The role of interleukin 1beta in the anti-adipogenic action of macrophages on human preadipocytes. J Endocrinol 2013; 217:197-206.
18. Kotnik P, Keuper M, Wabitsch M, Fischer-Posovszky P. Interleukin-1beta downregulates RBP4 secretion in human adipocytes. PLoS ONE 2013; 8:e57796.
19. Hotamisligil GS. Molecular mechanisms of insulin resistance and the role of the adipocyte. Int J Obes Relat Metab Disord 2000; 24 Suppl 4:S23-7.
20. Smith U. Impaired (‘diabetic’) insulin signaling and action occur in fat cells long before glucose intoleranceis insulin resistance initiated in the adipose tissue? Int J Obes Relat Metab Disord 2002; 26:897-904.
21. Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol 2006; 7:85-96.
22. Lumeng CN, Deyoung SM, Saltiel AR. Macrophages block insulin action in adipocytes by altering expression of signaling and glucose transport proteins. Am J Physiol Endocrinol Metab 2007; 292:E166-74.
23. Gao D, Madi M, Ding C, Fok M, Steele T, Ford C, et al. Interleukin-1beta mediates macrophage-induced impairment of insulin signaling in human primary adi- pocytes. Am J Physiol Endocrinol Metab 2014; 307: E289-304.
24. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259:87-91.
25. Stephens JM, Lee J, Pilch PF. Tumor necrosis factoralpha-induced insulin resistance in 3T3-L1 adipocytes is accompanied by a loss of insulin receptor substrate-1 and GLUT4 expression without a loss of insulin recep- tor-mediated signal transduction. J Biol Chem 1997; 272:971-6.
26. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997; 389:610-4.
27. Rotter V, Nagaev I, Smith U. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem 2003; 278:45777-84.
28. van Asseldonk EJ, Stienstra R, Koenen TB, van Tits LJ, Joosten LA, Tack CJ, et al. The effect of the interleukin-1 cytokine family members IL-1F6 and IL-1F8 on adipocyte differentiation. Obesity (Silver Spring) 2010; 18:2234-6.
29. Sims JE, Smith DE. The IL-1 family: regulators of immunity. Nat Rev Immunol 2010; 10:89-102.
30. Stienstra R, Joosten LA, Koenen T, van Tits B, van Diepen JA, van den Berg SA, et al. The inflammasome- mediated caspase-1 activation controls adipocyte 151 differentiation and insulin sensitivity. Cell Metab 2010; 12:593-605.
31. Tack CJ, Stienstra R, Joosten LA, Netea MG. Inflam- mation links excess fat to insulin resistance: the role of the interleukin-1 family. Immunological reviews 2012; 249:239-52.
32. Wen H, Gris D, Lei Y, Jha S, Zhang L, Huang MT, et al. Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nature immunology 2011; 12:408-15.
33. Fain JN. Release of interleukins and other inflamma- tory cytokines by human adipose tissue is enhanced in obesity and primarily due to the nonfat cells. Vitam Horm 2006; 74:443-77.
34. Koenen TB, Stienstra R, van Tits LJ, Joosten LA, van Velzen JF, Hijmans A, et al. The inflammasome and caspase-1 activation: a new mechanism underlying increased inflammatory activity in human visceral adi-pose tissue. Endocrinology 2011; 152:3769-78.
35. Lagathu C, Yvan-Charvet L, Bastard JP, Maachi M,Quignard-Boulange A, Capeau J, et al. Long-term treatment with interleukin-1beta induces insulin resis-tance in murine and human adipocytes. Diabetologia 2006; 49:2162-73.
36. Jager J, Gremeaux T, Cormont M, Le Marchand-Brustel Y, Tanti JF. Interleukin-1beta-induced insulin resistance in adipocytes through down-regulation of insulin receptor substrate-1 expression. Endocrinology 2007; 148:241-51.
37. Gao D, Bing C. Macrophage-induced expression and release of matrix metalloproteinase 1 and 3 by human 152 preadipocytes is mediated by IL-1beta via activation of MAPK signaling. J Cell Physiol 2011; 226:2869-80.
38. Gao D, Trayhurn P, Bing C. 1,25-Dihydroxyvitamin D3 inhibits the cytokine-induced secretion of MCP-1 and reduces monocyte recruitment by human preadipo- cytes. Int J Obes (Lond) 2013; 37:357-65.
39. Keophiphath M, Rouault C, Divoux A, Clement K, Lacasa D. CCL5 promotes macrophage recruitment and survival in human adipose tissue. Arterioscler Thromb Vasc Biol 2010; 30:39-45.
40. Kitade H, Sawamoto K, Nagashimada M, Inoue H, Yamamoto Y, Sai Y, et al. CCR5 plays a critical role in obesity-induced adipose tissue inflammation and insu- lin resistance by regulating both macrophage recruit- ment and M1/M2 status. Diabetes 2012; 61:1680-90.
41. Kanda H, Tateya S, Tamori Y, Kotani K, Hiasa K, Kitazawa R, et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 2006; 116:1494-505.
42. Tsou CL, Peters W, Si Y, Slaymaker S, Aslanian AM, Weisberg SP, et al. Critical roles for CCR2 and MCP3 in monocyte mobilization from bone marrow and recruitment to inflammatory sites. J Clin Invest 2007; 117:902-9.
43. Owyang AM, Maedler K, Gross L, Yin J, Esposito L, Shu L, et al. XOMA 052, an anti-IL-1{beta} monoclonal antibody, improves glucose control and {beta}-cell function in the diet-induced obesity mouse model. Endocrinology 2010; 151:2515-27.
44. McGillicuddy FC, Harford KA, Reynolds CM, Oliver E, Claessens M, Mills KH, et al. Lack of interleukin-1 receptor I (IL-1RI) protects mice from high-fat diet- induced adipose tissue inflammation coincident with improved glucose homeostasis. Diabetes 2011; 60:1688-98.
45. Ehses JA, Lacraz G, Giroix MH, Schmidlin F, Coulaud J, Kassis N, et al. IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat. Proc Natl Acad Sci U S A 2009; 106:13998-4003.
46. Sauter NS, Schulthess FT, Galasso R, Castellani LW, Maedler K. The antiinflammatory cytokine interleukin- 1 receptor antagonist protects from high-fat diet- induced hyperglycemia. Endocrinology 2008; 149:2208-18.
47. Larsen CM, Faulenbach M, Vaag A, Volund A, Ehses JA, Seifert B, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007; 356:1517-26.
48. Cavelti-Weder C, Babians-Brunner A, Keller C, Stahel MA, Kurz-Levin M, Zayed H, et al. Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes. Diabetes Care 2012; 35:1654-62.
49. Sloan-Lancaster J, Abu-Raddad E, Polzer J, Miller JW, Scherer JC, De Gaetano A, et al. Double-blind, randomized study evaluating the glycemic and anti-inflam- matory effects of subcutaneous LY2189102, a neutralizing IL-1beta antibody, in patients with type 2 diabetes. Diabetes Care 2013; 36:2239-46.